Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Septic shock patients, particularly those with ongoing tachycardia, who are treated with phenylephrine appears to be at greater risk of mortality, suggests a study.

Phenylephrine use ups mortality risk in septic shock patients

Combo therapy in IBD: Is de-escalation possible after 1 year?

15 Feb 2023 bởi

Clinicians should consider de-escalating combination therapy with immunomodulators to a monotherapy after 1 year in patients with inflammatory bowel disease (IBD), says an expert at Crohn’s and Colitis Congress 2023.

Combo therapy in IBD: Is de-escalation possible after 1 year?

Single-dose azithromycin during labour prevents maternal death, sepsis

15 Feb 2023 bởi

Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.

Single-dose azithromycin during labour prevents maternal death, sepsis

$Aspirin as good as heparin for thromboprophylaxis in patients with fractures$

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

Thromboprophylaxis with aspirin in patients with extremity fractures appears to prevent death and lower the incidences of deep-vein thrombosis and pulmonary embolism without any significant differences as compared with thromboprophylaxis with low-molecular-weight heparin, according to a study.

Aspirin as good as heparin for thromboprophylaxis in patients with fractures

14 Feb 2023

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

The selective neurokinin (NK)-1,3 receptor antagonist elinzanetant appears to be beneficial in the treatment of vasomotor symptoms (VMS) and associated sleep disturbance in postmenopausal women, as shown in the results of the phase IIb SWITCH-1 trial.

Elinzanetant a promising nonhormone treatment option for VMS, sleep problems

Statins reduce MACE in patients with normal MPI, elevated CAC score

Use of moderate to high-intensity statin (MHIS) following myocardial perfusion imaging (MPI) results in fewer major adverse cardiovascular events (MACE) and is independently predictive of 24-month MACE among patients with normal stress MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.

Statins reduce MACE in patients with normal MPI, elevated CAC score

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Compared with standard dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy after 1- to 3-month DAPT results in similar rates of fatal and ischaemic events, as well as lower major bleeding risk, regardless of percutaneous coronary intervention (PCI) complexity, according to a study.

P2Y12 inhibitor monotherapy on par with DAPT after complex PCI

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

Twice-yearly maintenance dosing of inclisiran reduces atherogenic lipoproteins for primary prevention of patients with elevated LDL-C* despite statin use, according to the analysis of the primary prevention cohort from the ORION-11 trial.

Infrequent inclisiran dosing effective for lipid-lowering in the primary prevention setting

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer

The use of liposomal irinotecan in combination with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX regimen) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) compared with gemcitabine plus nab-paclitaxel (Gem+NabP) in the first-line setting, according to the NAPOLI-3* trial presented at the ASCO GI 2023.

First-line NALIRIFOX regimen ups survival in metastatic pancreatic cancer